| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37549e0727671e86ec014524c6fc6992
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_756ca999dbdc457097471dbb51625628 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-80 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2014-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc1b3e58e7a546478190aaeb92d3d69f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb85e00d21c55d662f60f3bdcf8abb67 |
| publicationDate |
2016-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016354489-A1 |
| titleOfInvention |
Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease |
| abstract |
The present invention relates to the field of gene therapy and, more particularly, to methods for the prevention and/or treatment of non-alcoholic fatty liver disease (NAFLD). The viral vectors disclosed in the present invention are preferably parvoviral vector, more preferably adeno-associated vectors (AAV) containing the gene encoding Sirtuin 1 (Sirt1) in the prevention and/or treatment of NAFLD. The present invention also discloses the pharmaceutical compositions comprising the viral vector and the method of prevention and/or treatment of NAFLD and related diseases by the administration of said pharmaceutical compositions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113416729-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3634986-A4 |
| priorityDate |
2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |